Updates in the management of connective tissue disease-associated interstitial lung disease

被引：0

作者：

Kavadichanda, Chengappa ^{[1
]}

Naidu, G. S. R. S. N. K. ^{[2
]}

机构：

[1] Jawaharlal Inst Postgrad Med Educ & Res, Dept Clin Immunol, Pondicherry, India

[2] Post Grad Inst Med Educ & Res, Dept Internal Med, Chandigarh, India

来源：

INDIAN JOURNAL OF RHEUMATOLOGY | 2021年 / 16卷 / 05期

关键词：

Antifibrotic; biologicals; connective tissue disease-interstitial lung disease; treatment; CUTANEOUS SYSTEMIC-SCLEROSIS; STEM-CELL TRANSPLANTATION; DOUBLE-BLIND; PULSE CYCLOPHOSPHAMIDE; SUBGROUP ANALYSIS; OPEN-LABEL; RITUXIMAB; EFFICACY; SAFETY; NINTEDANIB;

D O I：

10.4103/0973-3698.332985

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The occurrence of interstitial lung disease (ILD) in a setting of a well-defined autoimmune disease or in the presence of autoantibodies is being increasingly recognized. The traditional approach to the treatment of connective tissue disease-associated ILD (CTD-ILD) was a combination of glucocorticoids and cyclophosphamide or mycophenolate mofetil. Most of the evidence in treating these cases is limited to a few trials in scleroderma and idiopathic pulmonary fibrosis along with several observational studies in other CTDs. Insights into the pathology of these diseases and the associated lung involvement have resulted in the emergence of several immunosuppressive, antifibrotic, and small molecules as alternatives in CTD-ILD. In this review, we have attempted to summarize several emerging therapeutic options for CTD-ILD.

引用

页码：109 / 115

页数：7

共 53 条

[1] A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis [J].

Allanore, Yannick ;

Wung, Peter ;

Soubrane, Christina ;

Esperet, Corinne ;

Marrache, Frederic ;

Bejuit, Raphael ;

Lahmar, Amel ;

Khanna, Dinesh ;

Denton, Christopher P. .

ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (12) :1600-1607

[2] Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease [J].

Andersson, Helena ;

Sem, Marthe ;

Lund, May Brit ;

Aalokken, Trond Mogens ;

Gunther, Anne ;

Walle-Hansen, Ragnhild ;

Garen, Torhild ;

Molberg, Oyvind .

RHEUMATOLOGY, 2015, 54 (08) :1420-1428

[3]

Atanelishvili Ilia, 2019, Clin Exp Rheumatol, V37 Suppl 119, P115

[4]

Avouac J, CLIN EXP RHEUMATOL

[5] Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial [J].

Azuma, Arata ;

Chung, Lorinda ;

Behera, Digambar ;

Chung, Melody ;

Kondoh, Yasuhiro ;

Ogura, Takashi ;

Okamoto, Masaki ;

Swarnakar, Rajesh ;

Zeng, Xiaofeng ;

Zou, Heijan ;

Meng, Xianhua ;

Gahlemann, Martina ;

Alves, Margarida ;

Kuwana, Masataka .

RESPIRATORY INVESTIGATION, 2021, 59 (02) :252-259

[6] Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response [J].

Bauhammer, Jutta ;

Blank, Norbert ;

Max, Regina ;

Lorenz, Hanns-Martin ;

Wagner, Ulrich ;

Krause, Dietmar ;

Fiehn, Christoph .

JOURNAL OF RHEUMATOLOGY, 2016, 43 (08) :1566-1574

[7] Alteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib [J].

Bellamri, Nessrine ;

Morzadec, Claudie ;

Joannes, Audrey ;

Lecureur, Valerie ;

Wollin, Lutz ;

Jouneau, Stephane ;

Vernhet, Laurent .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 72 :112-123

[8] Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial [J].

Burt, Richard K. ;

Shah, Sanjiv J. ;

Dill, Karin ;

Grant, Thomas ;

Gheorghiade, Mihai ;

Schroeder, James ;

Craig, Robert ;

Hirano, Ikuo ;

Marshall, Karin ;

Ruderman, Eric ;

Jovanovic, Borko ;

Milanetti, Francesca ;

Jain, Sandeep ;

Boyce, Kristin ;

Morgan, Amy ;

Carr, James ;

Barr, Walter .

LANCET, 2011, 378 (9790) :498-506

[9] Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial [J].

Chung, Lorinda ;

Spino, Cathie ;

McLain, Richard ;

Johnson, Sindhu R. ;

Denton, Christopher P. ;

Molitor, Jerry A. ;

Steen, Virginia D. ;

Lafyatis, Robert ;

Simms, Robert W. ;

Kafaja, Suzanne ;

Frech, Tracy M. ;

Hsu, Vivien ;

Domsic, Robyn T. ;

Pope, Janet E. ;

Gordon, Jessica K. ;

Mayes, Maureen D. ;

Sandorfi, Nora ;

Hant, Faye N. ;

Bernstein, Elana J. ;

Chatterjee, Soumya ;

Castelino, Flavia V. ;

Ajam, Ali ;

Allanore, Yannick ;

Matucci-Cerinic, Marco ;

Whitfield, Michael L. ;

Distler, Oliver ;

Singer, Ora ;

Young, Amber ;

Nagaraja, Vivek ;

Fox, David A. ;

Furst, Daniel E. ;

Khanna, Dinesh .

LANCET RHEUMATOLOGY, 2020, 2 (12) :E743-E753

[10] A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease [J].

Daoussis, Dimitrios ;

Melissaropoulos, Konstantinos ;

Sakellaropoulos, Georgios ;

Antonopoulos, Ioannis ;

Markatseli, Theodora E. ;

Simopoulou, Theodora ;

Georgiou, Panagiotis ;

Andonopoulos, Andrew P. ;

Drosos, Alexandros A. ;

Sakkas, Lazaros ;

Liossis, Stamatis-Nick .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017, 46 (05) :625-631

← 1 2 3 4 5 6 →